CORDIS
EU research results

CORDIS

English EN

Miltefosine for leishmaniasis: molecular basis of mechanisms of action, resistance and combination therapy (MILTLEISH)

Project information

Grant agreement ID: QLK2-CT-2001-01404

  • Start date

    1 November 2001

  • End date

    31 January 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 387 498

  • EU contribution

    € 987 940

Coordinated by:

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

United Kingdom

Objective

Miltefosine, an alkylphospholipid first developed as an anticancer drug, has been shown to have activity against Leis mania species and is a new oral drug for the treatment of visceral leishmaniasis. There is little understanding of the mechanism(s) of action or resistance of this drug in Leis mania. This project will characterise drug targets and resistance mechanisms in L.donovani through molecular/biochemical techniques and chemical structure-activity studies. Results will be used to design strategies to avoid or overcome drug resistance, including drug combinations. Target characterisation will be used as the basis for the identification of further antiprotozoal drugs.

Coordinator

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

Address

Keppel Street
London

United Kingdom

Participants (4)

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Spain

EUROPEPTIDES (GEIE)

France

FREIE UNIVERSITAET BERLIN

Germany

UNIVERSITE DE PARIS-SUD XI

France

Project information

Grant agreement ID: QLK2-CT-2001-01404

  • Start date

    1 November 2001

  • End date

    31 January 2005

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 387 498

  • EU contribution

    € 987 940

Coordinated by:

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

United Kingdom